Latest Interviews

Sharks Never Stop Swimming: A Conversation with Mark Cuban

Mark Cuban, David Ulevitch

Mark Cuban and Dr. Alex Oshmayansky have leveraged Cost Plus Drugs to expose pharmaceutical opacity by publishing exact medication costs with a fixed 15% markup, ultimately attracting Harvard and Vanderbilt researchers to project $3.6 billion in potential government savings. The company expanded its model to B2B wholesale and advocates for healthcare CFOs to negotiate rates at 80–100% of Medicare prices, challenging the three major Pharmacy Benefit Managers that currently dominate the market through rebate retention and regulatory capture. Beyond healthcare, Cuban utilizes these insights to critique rising tuition costs and *Shark Tank* dynamics, calling for structural reforms that prioritize middle-American entrepreneurs and eliminate non-transparent corporate contracts.